MIIMS: in relapsing MS, phase 2

What was tested

Treatment tested

HP 13C pyruvate injection
MRI Scanner

What it measured

Main measures

To determine the percent changes in MS lesions, white matter, and whole brain HP 13C pyruvate metabolism measures between the pre-treatment scan and the scan obtained 1.5-months following treatment initiation.
From study initiation to up to 15 months after enrollment of last subject.
MRI lesionsBrain volume lossHow the body handles the medicine

Other measures (2)

To determine the percent changes in MS lesions, white matter, and whole brain HP 13C pyruvate metabolism measures between the pre-treatment scan and the scan obtained 3-months and one year following treatment initiation.
From study initiation to up to 15 months after enrollment of last subject.
MRI lesionsBrain volume lossHow the body handles the medicine
To determine the repeatability of HP 13C pyruvate metabolism measures in the MS lesions in patients with same-day repeated dose.
From study initiation to 15 months after enrollment of last subject.
MRI lesionsHow the body handles the medicine

Who could take part

Relapsing MS · 18 and over

Show the full criteria

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Subjects must be 18 years or older. 2. Relapsing remitting MS, naïve to DMTs for the past two years minimum 3. Patients must be naive to anti-CD20 therapy with plans to begin the therapy as part of their physician's multiple sclerosis treatment plan. The patients must remain on a form of anti-CD20 therapy for the entirety of their enrollment in the study. 4. Patients enrolled will be screened for at least one MS lesion with a 10mm diameter in one plane.

Exclusion criteria

1. Treatment with corticosteroids within 30 days prior to screening. 2. Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips. 3. Poorly controlled hypertension, defined as either systolic >160 or diastolic >110. The addition of anti-hypertensives to control blood pressure is allowed for eligibility determination. 4. Congestive Heart Failure ≥ NYHA Class II. 5. History of clinically significant EKG abnormalities, including QT prolongation or a family history of prolonged QT syndrome. 6. Myocardial infarction within 6 months of study entry. 7. Individuals who are pregnant. Individuals of childbearing potential (defined below) must agree to undergo a urine pregnancy test prior to participating in the study scans. Pregnant individuals are excluded because there is an unknown but potential risk for adverse effects in the unborn child secondary to administration of HP 13C pyruvate to the study participant. A female is considered to not be of childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if they meet either of the following two criteria: (1) has reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries). 8. Individuals who are breastfeeding/chestfeeding. Breastfeeding/chestfeeding individuals are excluded because there is an unknown but potential risk for adverse effects in the unborn/nursing child secondary to administration of HP 13C pyruvate to the study participant. Breastfeeding/chestfeeding should be discontinued before administration of HP 13C pyruvate. 9. Known hypersensitivity to HP 13C pyruvate or any of its excipients. 10. History of cancer within five years of enrollment date and/or history of chemotherapy within two years of enrollment date. 11. Any dental braces or permanent or undetachable metals in the jaw or face. 12. Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, allergic, renal, or other major diseases that in the PI's judgment may affect the interpretation of study results or patient safety. 13. Individuals with any condition or social circumstance that, in the opinion of the investigator, would impair the participant's ability to comply with study procedures. 14. Glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m² on baseline visit or subsequent study visits, history of kidney disease or history of hypersensitivity to gadolinium contrast agent. 15. Baseline EDSS >6.5

As registered. Criteria can change, so ask the trial team or your neurologist.

Contact details on the registry

About this trial

In the sponsor's words

The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy. Study procedures will include magnetic resonance imaging (MRI) assessments with a hyperpolarized pyruvate sequence, clinical assessment as well as blood markers of disease progression. This method of imaging utilizes the Warburg effect, where innate immune cells utilize a metabolic shift to glycolysis instead of oxidative phosphorylation. In pre-clinical data, increased hyperpolarized lactate production has been found to be associated with increased microglial/macrophage infiltration in the brain. Although hyperpolarized carbon imaging in humans has been established and used in the field of oncology, this will be one of the first applications of hyperpolarized carbon the study of neuroinflammation in humans. We predict that hyperpolarized carbon imaging may have the potential to monitor and evaluate neuroinflammation in MS, and in particular the innate immune activation state that plays a role in MS progression. This imaging method may provide non-invasive monitoring of disease progression and therapy response for MS patients.

Papers

History

Started
Jun 2026
Main results due
Dec 2029
Finished
Dec 2029

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

What it found